PTC Therapeutics Stock Forecast, Price & News

-0.66 (-1.37 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $47.60
50-Day Range
MA: $54.70
52-Week Range
Now: $47.60
Volume14,467 shs
Average Volume551,060 shs
Market Capitalization$3.35 billion
P/E RatioN/A
Dividend YieldN/A
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
PTC Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PTCT
Year FoundedN/A



Sales & Book Value

Annual Sales$306.98 million
Book Value$9.64 per share


Net Income$-251,580,000.00
Net Margins-123.19%


Market Cap$3.35 billion
Next Earnings Date4/29/2021 (Estimated)


PTC Therapeutics (NASDAQ:PTCT) Stock Price Down 7.1%
March 23, 2021 |
PTC Therapeutics, Inc. to Host Earnings Call
February 25, 2021 |
See More Headlines


Overall MarketRank

1.28 out of 5 stars

Medical Sector

819th out of 2,011 stocks

Pharmaceutical Preparations Industry

393rd out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.66 (-1.37 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PTCT News and Ratings via Email

Sign-up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions

Is PTC Therapeutics a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last twelve months. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PTC Therapeutics stock.
View analyst ratings for PTC Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than PTC Therapeutics?

Wall Street analysts have given PTC Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PTC Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is PTC Therapeutics' next earnings date?

PTC Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for PTC Therapeutics

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) posted its quarterly earnings data on Thursday, February, 25th. The biopharmaceutical company reported ($1.08) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.90) by $0.18. The biopharmaceutical company had revenue of $118.86 million for the quarter, compared to analysts' expectations of $113.47 million. PTC Therapeutics had a negative trailing twelve-month return on equity of 76.10% and a negative net margin of 123.19%.
View PTC Therapeutics' earnings history

How has PTC Therapeutics' stock been impacted by Coronavirus (COVID-19)?

PTC Therapeutics' stock was trading at $47.08 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PTCT shares have increased by 1.1% and is now trading at $47.60.
View which stocks have been most impacted by COVID-19

What price target have analysts set for PTCT?

12 brokers have issued 1 year price targets for PTC Therapeutics' shares. Their forecasts range from $47.00 to $86.00. On average, they expect PTC Therapeutics' share price to reach $64.90 in the next twelve months. This suggests a possible upside of 36.3% from the stock's current price.
View analysts' price targets for PTC Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the following people:
  • Dr. Stuart W. Peltz, Co-Founder, CEO & Exec. Director (Age 61, Pay $1.44M)
  • Dr. Allan Steven Jacobson, Independent Co-Founder, Chairman of Scientific Advisory Board & Director (Age 75, Pay $140k)
  • Ms. Emily Luisa Hill, CFO & Treasurer (Age 40, Pay $607.45k)
  • Ms. Christine Utter, Sr. VP, Chief Accounting Officer & Head of People Services (Age 43, Pay $595.54k)
  • Dr. Neil Almstead, Chief Technical Operations Officer (Age 54, Pay $742.2k)
  • Mr. Mark Elliott Boulding, Exec. VP & Chief Legal Officer (Age 60, Pay $733.42k)
  • Dr. Mark Jerome Pykett, Chief Scientific Officer (Age 57)
  • Alex Kane, Investor Relations Officer
  • Ms. Jane Baj, VP of Corp. Communications
  • Ms. Hege Sollie-Zetlmayer, Sr. VP of HR

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics CEO Stuart W. Peltz on Stuart W. Peltz has an approval rating of 77% among PTC Therapeutics' employees.

Who are some of PTC Therapeutics' key competitors?

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Hexavest Inc. (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own PTC Therapeutics stock include Allan Steven Jacobson, Christine Marie Utter, Dawn Svoronos, Emily Luisa Hill, Eric Pauwels, Marcio Souza, Mark Elliott Boulding, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends for PTC Therapeutics

Which major investors are selling PTC Therapeutics stock?

PTCT stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., and Pacer Advisors Inc.. Company insiders that have sold PTC Therapeutics company stock in the last year include Allan Steven Jacobson, Christine Marie Utter, Dawn Svoronos, Emily Luisa Hill, Eric Pauwels, Mark Elliott Boulding, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey, and Stuart Walter Peltz.
View insider buying and selling activity for PTC Therapeutics
or view top insider-selling stocks.

How do I buy shares of PTC Therapeutics?

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $47.60.

How much money does PTC Therapeutics make?

PTC Therapeutics has a market capitalization of $3.35 billion and generates $306.98 million in revenue each year. The biopharmaceutical company earns $-251,580,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis.

How many employees does PTC Therapeutics have?

PTC Therapeutics employs 959 workers across the globe.

What is PTC Therapeutics' official website?

The official website for PTC Therapeutics is

Where are PTC Therapeutics' headquarters?

PTC Therapeutics is headquartered at 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]

This page was last updated on 4/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.